Abstract 5801
Background
Malignant tumors represent a major public health problem in the world and Mexico is not the exception. The development of Population-Based Cancer Registries (PBCR) that collect cancer cases in a determined locality and help evaluate health programs is fundamental. In Mexico there were only a couple of attempts on hospital and histopathological registries, reason why it was decided to implement a PBCR, named as the National Network of Cancer Registries (NNCR).
Methods
During the creation process, support was received from the International Agency of Research in Cancer (IARC), through the Global Initiative for Cancer Registry Development. The NNRC is operated in a central level located in Mexico City, and the cases in the sources of information established are registered in a national registration form composed of 29 variables structured and standardized according to international guidelines. The collection and administration of information is done through a technological system, called RedCancerMX in a mobile and web application hosted on the cloud.
Results
In 2016, the General Health Law was modified to create the National Cancer Registry and in 2017 it was approved. In July 2018 the regulations of the NNCR are published, which establishes the bases for organization, integration and coordination. To the date, the NNCR is active in 8 cities, reaching 10% of national coverage. The process of integration of each city to the NNCR, included a feasibility analysis, validation and training. The process of obtaining data covers subprocesses of collection, validation and authorization carried out by medical specialists. RedCancerMX had integrated 11 validations established by international organizations to guarantee the quality of the information and they are aligned to quality indicators proposed by the IARC: comparability, validity, timeliness and completeness.
Conclusions
In Mexico, the NNCR is already established, which is considered an epidemiological surveillance system with national, active and continuous validity. This NNCR will allow us to determine the incidence of cancer and survival rates in the Mexican population, helping to implement new and better strategies for cancer control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Nacional de Cancerología.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract